GSIE - ETF AI Analysis
Top Page
Goldman Sachs ActiveBeta International Equity ETF (GSIE)
Rating:65Neutral
Price Target:―
Positive Factors
Broad International Diversification
The fund spreads its investments across many countries such as Japan, the UK, Europe, Canada, and others, which helps reduce the impact of problems in any single market.
Healthy Sector Mix
Holdings are spread across financials, industrials, technology, health care, and several other sectors, limiting reliance on just one part of the economy.
Competitive Expense Ratio
The fund’s expense ratio is relatively low for an actively managed international strategy, helping investors keep more of their returns over time.
Negative Factors
Heavy Tilt Toward Financials
With a large share of assets in financial companies, the fund is more exposed to risks specific to banks and other financial institutions.
Mixed Performance Among Top Holdings
While some leading positions like ASML, Roche, and Advantest have shown strong gains, others such as Royal Bank of Canada, AstraZeneca, SAP, and Allianz have been weaker, which can dampen overall results.
Limited U.S. Exposure
The fund has only a modest allocation to U.S. stocks, so investors who want significant exposure to the U.S. market would need to pair it with another fund.
GSIE vs. SPDR S&P 500 ETF (SPY)
AUM5.53B
RegionDeveloped Markets
Expense Ratio0.25%
Beta0.72
IssuerGoldman Sachs
Inception DateNov 06, 2015
Dividend Yield2.55%
Asset ClassEquity
Index TrackedStuttgart Goldman Sachs ActiveBeta Intl.Equity (USD)
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume365,875
30 Day Avg. Volume553,988
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
51.10Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering649
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
GSIE Summary
GSIE is the Goldman Sachs ActiveBeta International Equity ETF, which follows the Stuttgart Goldman Sachs ActiveBeta International Equity index and invests in stocks from countries outside the U.S., such as Japan, the UK, and Germany. It owns many types of companies across sectors like finance, industrials, health care, and technology, including well-known names like ASML, Novartis, and HSBC. Investors might consider GSIE to diversify beyond the U.S. and spread their money across many international companies for long-term growth. A key risk is that international stock prices can be volatile and move up or down with global markets and currency changes.
How much will it cost me?The expense ratio for the Goldman Sachs ActiveBeta International Equity ETF (GSIE) is 0.25%, which means you’ll pay $2.50 per year for every $1,000 invested. This is lower than average for actively managed ETFs because it uses a factor-based strategy rather than traditional stock-picking, keeping costs relatively modest.
What would affect this ETF?The GSIE ETF, with its focus on developed markets outside the U.S., could benefit from economic growth in Europe and Asia, particularly if industries like financials and technology, which have significant weight in the fund, experience expansion. However, it may face challenges from rising interest rates or geopolitical tensions that could negatively impact international markets and sectors like financials and consumer cyclical. Additionally, regulatory changes in key regions or currency fluctuations could influence the ETF's performance.
GSIE Top 10 Holdings
GSIE’s story is all about international blue chips, with a clear tilt toward big banks and global health care. Financial heavyweights like Royal Bank of Canada, HSBC, and Banco Santander have been lagging lately, acting as a bit of a brake on the fund. On the flip side, semiconductor names such as ASML and Advantest, along with energy giant Shell, have been rising and doing much of the heavy lifting. Nestlé and Novartis are steadier anchors, keeping this developed-markets-ex-U.S. portfolio broadly diversified despite a few soft spots.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| ASML Holding NV | 1.86% | $101.66M | €471.67B | 116.01% | 76 Outperform | |
| Novartis AG | 1.12% | $61.21M | CHF223.05B | 44.23% | 80 Outperform | |
| HSBC Holdings | 1.04% | $57.18M | £229.16B | 81.76% | 80 Outperform | |
| Roche Holding AG | 1.02% | $55.62M | $320.22B | 29.20% | 73 Outperform | |
| AstraZeneca | 0.96% | $52.77M | $318.08B | 52.48% | 80 Outperform | |
| Royal Bank Of Canada | 0.96% | $52.36M | $238.31B | 55.33% | 75 Outperform | |
| Banco Santander | 0.80% | $44.05M | €151.84B | 83.96% | 73 Outperform | |
| Advantest | 0.74% | $40.27M | ¥17.30T | 256.42% | 75 Outperform | |
| Shell (UK) | 0.70% | $38.17M | £193.37B | 48.26% | 73 Outperform | |
| Toronto Dominion Bank | 0.67% | $36.45M | $168.62B | 76.32% | 74 Outperform |
GSIE Technical Analysis
Positive
―
Price Trends
44.42
Positive
43.45
Positive
41.79
Positive
Market Momentum
0.06
Negative
60.92
Neutral
90.76
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For GSIE, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 43.12, equal to the 50-day MA of 44.42, and equal to the 200-day MA of 41.79, indicating a bullish trend. The MACD of 0.06 indicates Negative momentum. The RSI at 60.92 is Neutral, neither overbought nor oversold. The STOCH value of 90.76 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GSIE.
GSIE Peer Comparison
Comparison Results
Performance Comparison
GSIE
Goldman Sachs ActiveBeta International Equity ETF
45.21
11.49
34.07%
LVHI
Legg Mason International Low Volatility High Dividend ETF
―
―
―
IMTM
iShares MSCI Intl Momentum Factor ETF
―
―
―
INTF
iShares MSCI Intl Multifactor ETF
―
―
―
IDMO
Invesco S&P International Developed Momentum ETF
―
―
―
PXF
Invesco FTSE RAFI Developed Markets ex-U.S. ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents